Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
Más filtros

Medicinas Complementárias
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Curr Osteoporos Rep ; 18(3): 273-284, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32285249

RESUMEN

PURPOSE OF REVIEW: Calcium and vitamin D supplementation is recommended for patients at high risk of fracture and/or for those receiving pharmacological osteoporosis treatments. Probiotics are micro-organisms conferring a health benefit on the host when administered in adequate amounts, likely by influencing gut microbiota (GM) composition and/or function. GM has been shown to influence various determinants of bone health. RECENT FINDINGS: In animal models, probiotics prevent bone loss associated with estrogen deficiency, diabetes, or glucocorticoid treatments, by modulating both bone resorption by osteoclasts and bone formation by osteoblast. In humans, they interfere with 25-hydroxyvitamin D levels, and calcium intake and absorption, and slightly decrease bone loss in elderly postmenopausal women, in a quite similar magnitude as observed with calcium ± vitamin D supplements. A dietary source of probiotics is fermented dairy products which can improve calcium balance, prevent secondary hyperparathyroidism, and attenuate age-related increase of bone resorption and bone loss. Additional studies are required to determine whether probiotics or any other interventions targeting GM and its metabolites may be adjuvant treatment to calcium and vitamin D or anti-osteoporotic drugs in the general management of patients with bone fragility.


Asunto(s)
Resorción Ósea/prevención & control , Complicaciones de la Diabetes/prevención & control , Osteoporosis/prevención & control , Probióticos/uso terapéutico , Conservadores de la Densidad Ósea/uso terapéutico , Resorción Ósea/microbiología , Calcio/metabolismo , Calcio/uso terapéutico , Productos Lácteos Cultivados , Complicaciones de la Diabetes/microbiología , Diabetes Mellitus , Microbioma Gastrointestinal , Glucocorticoides/efectos adversos , Humanos , Osteoblastos , Osteoclastos , Osteogénesis , Osteoporosis/etiología , Osteoporosis/microbiología , Osteoporosis Posmenopáusica/microbiología , Osteoporosis Posmenopáusica/prevención & control , Vitamina D/uso terapéutico
2.
Sci Rep ; 10(1): 2854, 2020 02 18.
Artículo en Inglés | MEDLINE | ID: mdl-32071320

RESUMEN

The current study aimed to formulate Selenium-Chitosan-Mupirocin (M-SeNPs-CCH) complex. The nanohybrid system was prepared using chitosan-cetyltrimethylammonium bromide (CTAB)-based hydrogel (CCH) that entrapped mupirocin (M) and selenium nanoparticles (SeNPs). The in vitro studies were performed by evaluation of the antibacterial activity and toxicity on L929 mouse fibroblast cell line. The in vivo study was conducted on rat diabetic wound infection model that was infected by mupirocin-methicillin-resistant Staphylococcus aureus (MMRSA). The wounds were treated by M-SeNPs-CCH nanohybrid system with concentrations of M; 20 mg/ml, CCH; 2 mg/ml and SeNPs; 512 µg/ml in two times/day for 21 days. The therapeutic effect of this nanohybrid system was evaluated by monitoring wound contraction and histopathological changes. Evaluation of the average wound healing time showed a significant difference between the treatment and control groups (P≤0.05). The histopathological study indicated that the amount of wound healing was considerable in M-SeNPs-CCH nanohybrid system groups compared to the control and M groups. The M-SeNPs-CCH nanohybrid system formulated in this study was able to reduce 3-fold MIC of mupirocin with synergistic antibacterial activity as well as to play a significant role in wound contraction, angiogenesis, fibroblastosis, collagenesis, proliferation of hair follicle, and epidermis growth compared to the control group (P ≤ 0.05). This research suggests that this nanohybrid system might be a development for the treatment of diabetic wound infection at mild stage.


Asunto(s)
Antibacterianos/farmacología , Complicaciones de la Diabetes/tratamiento farmacológico , Cicatrización de Heridas/efectos de los fármacos , Infección de Heridas/tratamiento farmacológico , Animales , Antibacterianos/química , Quitosano/química , Quitosano/farmacología , Complicaciones de la Diabetes/microbiología , Complicaciones de la Diabetes/patología , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Humanos , Mupirocina/química , Mupirocina/farmacología , Nanoestructuras/química , Ratas , Selenio/química , Selenio/farmacología , Infección de Heridas/microbiología , Infección de Heridas/patología
3.
Arch Microbiol ; 202(5): 953-965, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32016521

RESUMEN

Diabetes mellitus is associated with various types of infections notably skin, mucous membrane, soft tissue, urinary tract, respiratory tract and surgical and/or hospital-associated infections. The reason behind this frequent association with infections is an immunocompromised state of diabetic patient because uncontrolled hyperglycemia impairs overall immunity of diabetic patient via involvement of various mechanistic pathways that lead to the diabetic patient as immunocompromised. There are specific microbes that are associated with each type of infection and their presence indicates specific type of infections. For instance, E. coli and Klebsiella are the most common causative pathogens responsible for the development of urinary tract infections. Diabetic-foot infections commonly occur in diabetic patients. In this article, we have mainly focused on the association of diabetes mellitus with various types of bacterial infections and the pattern of resistance against antimicrobial agents that are frequently used for the treatment of diabetes-associated infections. Moreover, we have also summarized the possible treatment strategies against diabetes-associated infections.


Asunto(s)
Bacterias/efectos de los fármacos , Infecciones Bacterianas/tratamiento farmacológico , Complicaciones de la Diabetes/microbiología , Diabetes Mellitus/inmunología , Huésped Inmunocomprometido/inmunología , Antibacterianos/farmacología , Bacterias/clasificación , Bacterias/aislamiento & purificación , Infecciones Bacterianas/microbiología , Complicaciones de la Diabetes/tratamiento farmacológico , Diabetes Mellitus/patología , Farmacorresistencia Bacteriana/efectos de los fármacos , Femenino , Humanos , Hiperglucemia/patología , Masculino , Pruebas de Sensibilidad Microbiana , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones del Sistema Respiratorio/microbiología , Infecciones Urinarias/tratamiento farmacológico , Infecciones Urinarias/microbiología
4.
Braz. j. microbiol ; 49(1): 152-161, Jan.-Mar. 2018. tab, graf
Artículo en Inglés | LILACS | ID: biblio-889202

RESUMEN

ABSTRACT The present investigation was designed to study the effect of an active compound isolated from Justicia wynaadensis against multi drug resistant organisms (MDRO's) associated with diabetic patients. The drug resistant pathogens implicated in wound and urinary tract infection of diabetic patients were isolated and identified by molecular sequencing. Solvent-solvent fractionation of crude methanol extract produced hexane, chloroform, ethyl acetate and methanol-water fraction, among which chloroform fraction was found to be potent when compared with other three fractions. Further, chloroform fraction was subjected to preparatory HPLC (High-Performance Liquid Chromatography), that produced four sub-fractions; chloroform HPLC fraction 1 (CHF1) through CHF4. Among the sub-fractions, CHF1 inhibited the pathogens effectively in comparison to other three sub-fractions. The purity of CHF1 was found to be >95%. Therefore, CHF1 was further characterized by NMR and FTIR analysis and based on the structure elucidated, the compound was found to be 3,3',4'-Trihydroxyflavone. The effective dose of this bioactive compound ranged from 32 µg/mL to 1.2 mg/mL. Thus, the present study shows that 3,3',4'-Trihydroxyflavone isolated from J. wynaadensis is an interesting biopharmaceutical agent and could be considered as a source of antimicrobial agent for the treatment of various infections and used as a template molecule for future drug development.


Asunto(s)
Humanos , Antibacterianos/farmacología , Bacterias/efectos de los fármacos , Complicaciones de la Diabetes/microbiología , Flavonoles/farmacología , Justicia Social/química , Extractos Vegetales/farmacología , Infecciones Urinarias/microbiología , Heridas y Lesiones/microbiología , Antibacterianos/química , Antibacterianos/aislamiento & purificación , Fenómenos Fisiológicos Bacterianos , Bacterias/genética , Bacterias/aislamiento & purificación , Flavonoles/química , Flavonoles/aislamiento & purificación , Pruebas de Sensibilidad Microbiana , Extractos Vegetales/química , Extractos Vegetales/aislamiento & purificación , Hojas de la Planta/química
5.
Rev. otorrinolaringol. cir. cabeza cuello ; 78(1): 36-42, mar. 2018. tab, graf, ilus
Artículo en Español | LILACS | ID: biblio-902812

RESUMEN

RESUMEN Introducción: La otomicosis en pacientes inmunosuprimidos esta caracterizada por ser bilateral y ser causada por candida. Pocos estudios comparan las características micológicas encontradas en la microscopía directa y el cultivo. Objetivo: Identificar las características clínicas y micológicas de la otomicosis en pacientes diabéticos. Material y método: Estudio transversal en centro hospitalario de segundo nivel. Criterios de inclusión: pacientes diabéticos con diagnóstico clínico de otomicosis. Intervención: la muestra se examinó directamente bajo el microscopio y se cultivó. Resultados: Se incluyeron 17 pacientes, 10 mujeres y 7 hombres con una edad media de 47,5 años. Los síntomas predominantes fueron hipoacusia en 91,4% (n =16), prurito en 82,4% (n =14), otorrea en 76,5% (n=13)y otalgia en 70,6% (n =12). Afección bilateral se encontró en 47,1% (n =8). Estudio directo al microscopio mostró levaduras en 94,1% (n =16) y 5,9% mostró aspergillus (n =1). Cándida fue el género más comúnmente encontrado en los cultivos y en el examen directo microscópico con 94,1% (n =16) y Candida albicans la especie más común con 88,2% (n =15). Conclusión: Candida albicans es el agente etiológico más común en pacientes diabéticos con otomicosis. Su presentación clínica más frecuente es hipoacusia, prurito y otorrea. El examen directo identificó adecuadamente a los géneros fúngicos.


ABSTRACT Introduction: Otomycosis in immunocompromised patients is characterize by its bilateral course and the predominant etiologic agent is Candida. Few studies compare the mycological features between microscopic direct exam and culture. Aim: To identify the clinical and mycological characteristics of otomycosis in diabetic patients. Material and method: Transversal study. Secondary care center. Inclusion criteria: diabetic patients with clinical diagnosis of otomycosis. Intervention: Direct examination under a microscope of the ear sample and culture. Results: We included 17 patients, 10 women, 7 men with a mean age of 47.5 years. Symptoms were hearing loss 94.1% (n = 16), pruritus 82.4% (n =14) otorrhoea 76.5% (n =13) and otalgia 70.6% (n =12). Bilateral involvement was found in 47.1% (n =8). Direct microscopic study found 94.1% of yeast (n =16) and 5.9% of Aspergillus (n =1). Candida was the most common fungal genus in culture and microscopic exam with 94.1% (n =16) of cases and Candida albicans was the most common species in 88.2% (n =15) cases. Conclusion: Candida albicans is the most common etiologic agent in diabetic patients with otomycosis. Main symptoms were hearing loss, itching and otorrhea. Direct exam correctly identified the fungal genus.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Complicaciones de la Diabetes/microbiología , Otomicosis/microbiología , Aspergillus fumigatus/aislamiento & purificación , Estaciones del Año , Factores de Tiempo , Infecciones Oportunistas , Candida albicans/aislamiento & purificación , Evolución Clínica , Estudios Transversales , Candida glabrata/aislamiento & purificación , Complicaciones de la Diabetes/epidemiología , Otomicosis/epidemiología
6.
Braz J Microbiol ; 49(1): 152-161, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-28870433

RESUMEN

The present investigation was designed to study the effect of an active compound isolated from Justicia wynaadensis against multi drug resistant organisms (MDRO's) associated with diabetic patients. The drug resistant pathogens implicated in wound and urinary tract infection of diabetic patients were isolated and identified by molecular sequencing. Solvent-solvent fractionation of crude methanol extract produced hexane, chloroform, ethyl acetate and methanol-water fraction, among which chloroform fraction was found to be potent when compared with other three fractions. Further, chloroform fraction was subjected to preparatory HPLC (High-Performance Liquid Chromatography), that produced four sub-fractions; chloroform HPLC fraction 1 (CHF1) through CHF4. Among the sub-fractions, CHF1 inhibited the pathogens effectively in comparison to other three sub-fractions. The purity of CHF1 was found to be >95%. Therefore, CHF1 was further characterized by NMR and FTIR analysis and based on the structure elucidated, the compound was found to be 3,3',4'-Trihydroxyflavone. The effective dose of this bioactive compound ranged from 32µg/mL to 1.2mg/mL. Thus, the present study shows that 3,3',4'-Trihydroxyflavone isolated from J. wynaadensis is an interesting biopharmaceutical agent and could be considered as a source of antimicrobial agent for the treatment of various infections and used as a template molecule for future drug development.


Asunto(s)
Antibacterianos/farmacología , Bacterias/efectos de los fármacos , Complicaciones de la Diabetes/microbiología , Flavonoles/farmacología , Género Justicia/química , Extractos Vegetales/farmacología , Infecciones Urinarias/microbiología , Heridas y Lesiones/microbiología , Antibacterianos/química , Antibacterianos/aislamiento & purificación , Bacterias/genética , Bacterias/aislamiento & purificación , Fenómenos Fisiológicos Bacterianos , Flavonoles/química , Flavonoles/aislamiento & purificación , Humanos , Pruebas de Sensibilidad Microbiana , Extractos Vegetales/química , Extractos Vegetales/aislamiento & purificación , Hojas de la Planta/química
7.
J Pak Med Assoc ; 66(10): 1291-1295, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27686306

RESUMEN

Objective: To determine the antimicrobial susceptibility of the most common bacterial and fungal infections among infected diabetic patients. Methods: This study was conducted at the Umm Al-Qura University, Makkah, Saudi Arabia, from June 2011 to June 2012, and comprised specimens collected from diabetics. Antibiotic susceptibility test using disc diffusion method was performed for bacterial isolates, and antifungal susceptibility test using colorimetric method for candida isolates. Results: Of the 138 specimens, antibacterial susceptibility test was performed for 129(93.5%) bacterial isolates while antifungal resistance test was performed for 9(6.5%) candida isolates. Of the bacterial isolates, 27(20.9%) were escherichia coli, 26(20.1%) staphylococcus aureus and 15(11.6%) were pseudomonas aeruginosa isolates. All Escherichia coli and staphylococcus aureus were susceptible to amikacin and vancomycin (100% each). Moreover, all candida species were susceptible to amphotericin B, econazole, fluconazole, ketoconazole and nystatin (100% each). CONCLUSIONS: The most effective antibiotics for bacterial infections among diabetic patients were vancomycin for gram-positive bacteria, amikacin for gram-negative bacteria and for bacteria isolated from diabetic patients with foot infections.


Asunto(s)
Antibacterianos/uso terapéutico , Complicaciones de la Diabetes/tratamiento farmacológico , Fungemia/tratamiento farmacológico , Bacterias Gramnegativas/aislamiento & purificación , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Antiinfecciosos , Infecciones Bacterianas , Complicaciones de la Diabetes/microbiología , Diabetes Mellitus , Farmacorresistencia Bacteriana , Bacterias Gramnegativas/efectos de los fármacos , Humanos , Pruebas de Sensibilidad Microbiana , Micosis , Arabia Saudita
8.
J Mycol Med ; 26(1): e6-10, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26849903

RESUMEN

Candida albicans is the common cause of some infectious diseases such as vaginal candidiasis or candidemia. Due to the emergence of drug resistant isolates of C. albicans, finding a new anti-Candida agent is a new strategy for current treatments. This study evaluated the anti-candidal activity of Satureja khuzistanica ethanol extract against clinical isolates of C. albicans. S. khuzistanica ethanol extract from aerial parts of plant at full flowering stage was evaluated against 30 clinical isolates and two ATCC reference strains of C. albicans by disc diffusion and micro-broth dilution assay. Also, in this study we evaluated the synergistic effects of amphotericin B, clotrimazole and ketoconazole with S. khuzistanica ethanol extract. The means of MIC and MFC of S. khuzistanica ethanol extract against clinical isolates were 299.4 and 722.6 (µg/mL), respectively. S. khuzistanica ethanol extract increased the anti-candidal effect of amphotericin B and ketoconazole, while it had no synergistic effect on clotrimazole against clinical isolates of C. albicans. Therefore, S. khuzistanica ethanol extract can be introduced as a new source of anti-candidal agent against clinical isolates of C. albicans.


Asunto(s)
Antifúngicos/farmacología , Candida albicans/efectos de los fármacos , Extractos Vegetales/farmacología , Satureja/química , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Anfotericina B/farmacología , Candidiasis/microbiología , Clotrimazol/farmacología , Complicaciones de la Diabetes/microbiología , Interacciones Farmacológicas , Femenino , Humanos , Cetoconazol/farmacología , Masculino , Pruebas de Sensibilidad Microbiana/métodos , Componentes Aéreos de las Plantas/química , Vagina/microbiología
9.
J Diabetes Res ; 2016: 6573215, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26844231

RESUMEN

Diabetic patients have higher risk of urinary tract infection (UTI). In the present study, we investigated the impact of glycemic control in diabetic patients on UTI prevalence, type of strains, and their antimicrobial drugs susceptibility. This study was conducted on urine samples from 722 adult diabetic patients from which 252 (35%) samples were positive for uropathogens. Most UTI cases occurred in the uncontrolled glycemic group (197 patients) versus 55 patients with controlled glycemia. Higher glycemic levels were measured in uncontrolled glycemia group (HbA1c = 8.3 ± 1.5 and 5.4 ± 0.4, resp., P < 0.0001). Females showed much higher prevalence of UTI than males in both glycemic groups (88.5% and 11.5%, resp., P < 0.0001). In the uncontrolled glycemia group 90.9% of the UTI cases happened at ages above 40 years and a clear correlation was obtained between patient age ranges and number of UTI cases (r = 0.94; P = 0.017), whereas in the group with controlled glycemia no trend was observed. Escherichia coli was the predominant uropathogen followed by Klebsiella pneumoniae and they were together involved in 76.2% of UTI cases. Those species were similarly present in both diabetic groups and displayed comparable antibiotic resistance pattern. These results highlight the importance of controlling glycemia in diabetic patients to reduce the UTI regardless of age and gender.


Asunto(s)
Antibacterianos/uso terapéutico , Complicaciones de la Diabetes/microbiología , Diabetes Mellitus/microbiología , Hiperglucemia/microbiología , Infecciones Urinarias/complicaciones , Infecciones Urinarias/tratamiento farmacológico , Adulto , Factores de Edad , Anciano , Glucemia , Escherichia coli , Femenino , Humanos , Hiperglucemia/complicaciones , Klebsiella pneumoniae , Kuwait/epidemiología , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Prevalencia , Riesgo , Urinálisis , Infecciones Urinarias/epidemiología
10.
Pak J Pharm Sci ; 28(6): 1985-90, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26639493

RESUMEN

Microbial resistance to existing antibiotics has led to an increase in the use of medicinal plants that show beneficial effects for various infectious diseases. The study evaluates the susceptibility of multidrug resistant Staphylococcus aureus to Nigella sativa oil. Staphylococcus aureus was isolated from 34 diabetic patient's wounds attending the Renaissance hospital, Nsukka, Southeast Nigeria. The isolates were characterized and identified using standard microbiological techniques. Isolates were cultured and a comparative In vitro antibiotic susceptibility test was carried out using the disk diffusion method. Of the 34 samples collected, 19(56%) showed multidrug resistance to the commonly used antibiotics. Nigella sativa oil was then studied for antibacterial activity against these multidrug resistant isolates of Staphylococcus aureus in varying concentration by well diffusion method. The oil showed pronounced dose dependent antibacterial activity against the isolates. Out of 19 isolates, 8(42%) were sensitive to undiluted oil sample; 4(21%) of these showed sensitivity at 200 mg/ml, 400 mg/ml and 800 mg/ml respectively. Eleven (58%) of the isolates were completely resistant to all the oil concentrations. The present study, reports the isolation of multi-drug resistant S. aureus from diabetic wounds and that more than half of isolates were susceptible to different concentrations N. sativa oil.


Asunto(s)
Antibacterianos/farmacología , Complicaciones de la Diabetes/tratamiento farmacológico , Farmacorresistencia Bacteriana Múltiple , Nigella sativa , Extractos Vegetales/farmacología , Aceites de Plantas/farmacología , Semillas , Infecciones Cutáneas Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus/efectos de los fármacos , Infección de Heridas/tratamiento farmacológico , Antibacterianos/aislamiento & purificación , Complicaciones de la Diabetes/diagnóstico , Complicaciones de la Diabetes/microbiología , Pruebas Antimicrobianas de Difusión por Disco , Relación Dosis-Respuesta a Droga , Humanos , Nigella sativa/química , Nigeria , Fitoterapia , Extractos Vegetales/aislamiento & purificación , Aceites de Plantas/aislamiento & purificación , Plantas Medicinales , Semillas/química , Infecciones Cutáneas Estafilocócicas/diagnóstico , Infecciones Cutáneas Estafilocócicas/microbiología , Staphylococcus aureus/aislamiento & purificación , Infección de Heridas/diagnóstico , Infección de Heridas/microbiología
11.
Orv Hetil ; 156(1): 28-31, 2015 Jan 04.
Artículo en Húngaro | MEDLINE | ID: mdl-25544052

RESUMEN

INTRODUCTION: Vulvovaginal candidiasis is the most common mycosis, however, the available information about antifungal susceptibilities of these yeasts is limited. AIM: To compare the gold standard fungal culture with a new molecular identification method and report the incidence of yeast species in vulvovaginitis candidosa. METHOD: The authors studied 370 yeasts isolated from vulvovaginal candidiasis and identified them by phenotypic and molecular methods. RESULTS: The most common species was Candida albicans (85%), followed by Candida glabrata, and other Candida species. CONCLUSION: At present there are no recommendations for the evaluation of antifungal susceptibility of pathogenic fungal species occurring in vulvovaginal candidiasis and the natural antifungal resistance of the different species is known only. Matrix Assisted Laser Desorption Ionization Time of Flight identification can be used to differentiate the fluconazole resistant Candida dubliniensis and the sensitive Candida albicans strains.


Asunto(s)
Antifúngicos/uso terapéutico , Candida/aislamiento & purificación , Candidiasis Vulvovaginal/diagnóstico , Candidiasis Vulvovaginal/tratamiento farmacológico , Administración Intravaginal , Administración Oral , Adulto , Anciano , Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Antifúngicos/administración & dosificación , Candida albicans/aislamiento & purificación , Candida glabrata/aislamiento & purificación , Candida tropicalis/aislamiento & purificación , Anticonceptivos Orales/administración & dosificación , Anticonceptivos Orales/efectos adversos , Complicaciones de la Diabetes/microbiología , Femenino , Fluconazol/uso terapéutico , Humanos , Hungría , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo
12.
J Periodontol ; 86(4): 516-26, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25494658

RESUMEN

BACKGROUND: Although patients with diabetes are frequently affected by periodontitis, only a few investigations have focused on gingivitis in this at-risk population. This randomized placebo-controlled clinical trial compared the response to a gingivitis treatment protocol that combined mechanical procedures and daily use of an essential oil (EO) mouthrinse between patients with and without diabetes. METHODS: The whole-mouth periodontal probing depth (PD), gingival index (GI), and plaque index (PI) were monitored in gingivitis cases among systemically healthy patients (n = 60) or those with diabetes (n = 60) at baseline and 3 months after treatment. Levels of Porphyromonas gingivalis, Tannerella forsythia, Aggregatibacter actinomycetemcomitans, and total bacterial load were determined by a real-time polymerase chain reaction in intrasulci plaque samples. The volume of gingival crevicular fluid (GCF) was quantified, and interleukin-1ß (IL-1ß) levels were determined in GCF samples. After a full-mouth ultrasonic debridement, patients were randomly assigned to an EO or a placebo rinse for 90 days (40 mL/day). The data were analyzed through repeated-measures analysis of variance and multiple comparisons Tukey tests (P <0.05). RESULTS: GI was more severe in the diabetes group. Diabetes impaired GI and reduced GCF volume. PD, bacterial levels, and IL-1ß improved similarly in both systemic conditions. The adjunctive use of EO provided greater reductions of PI, GI, total bacterial load, T. forsythia, A. actinomycetemcomitans, and GCF volume. CONCLUSIONS: Response to gingivitis treatment in patients with diabetes can slightly differ from that in patients without diabetes. Daily use of an EO mouthrinse after ultrasonic debridement benefited patients with and without diabetes.


Asunto(s)
Complicaciones de la Diabetes , Gingivitis/terapia , Adulto , Aggregatibacter actinomycetemcomitans/efectos de los fármacos , Aggregatibacter actinomycetemcomitans/aislamiento & purificación , Carga Bacteriana/efectos de los fármacos , Bacteroides/efectos de los fármacos , Bacteroides/aislamiento & purificación , Placa Dental/microbiología , Índice de Placa Dental , Complicaciones de la Diabetes/inmunología , Complicaciones de la Diabetes/microbiología , Método Doble Ciego , Femenino , Estudios de Seguimiento , Líquido del Surco Gingival/química , Líquido del Surco Gingival/inmunología , Gingivitis/inmunología , Gingivitis/microbiología , Humanos , Interleucina-1beta/análisis , Masculino , Persona de Mediana Edad , Antisépticos Bucales/uso terapéutico , Aceites Volátiles/uso terapéutico , Desbridamiento Periodontal/métodos , Índice Periodontal , Bolsa Periodontal/clasificación , Placebos , Porphyromonas gingivalis/efectos de los fármacos , Porphyromonas gingivalis/aislamiento & purificación , Adulto Joven
13.
Acta Pol Pharm ; 70(4): 587-96, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23923382

RESUMEN

Diabetes mellitus is one of the main risk factors of fungal infections of oral cavity, lower part of gastrointestinal tract, skin, foot, urogenital system and blood. Mycosis is a serious diagnostic and therapeutic problem and cause of mortality in diabetes. Fungal infections are also an important problem among hemodialysis patients with diabetes or diabetic patients after pancreas or kidney transplantation This work briefly describes the etiology, symptoms, diagnosis and ways of prophylaxis and treatment of mycosis in diabetic population. There is also emphasized the great connection between effective treatment of mycosis and glycemic control.


Asunto(s)
Antifúngicos/uso terapéutico , Complicaciones de la Diabetes/tratamiento farmacológico , Micosis/tratamiento farmacológico , Complicaciones de la Diabetes/diagnóstico , Complicaciones de la Diabetes/microbiología , Complicaciones de la Diabetes/mortalidad , Complicaciones de la Diabetes/prevención & control , Humanos , Trasplante de Riñón/efectos adversos , Pruebas de Sensibilidad Microbiana , Micosis/diagnóstico , Micosis/microbiología , Micosis/mortalidad , Micosis/prevención & control , Trasplante de Páncreas/efectos adversos , Diálisis Renal/efectos adversos , Factores de Riesgo , Resultado del Tratamiento
15.
J Microbiol Immunol Infect ; 44(3): 166-71, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21524609

RESUMEN

BACKGROUND: Candida albicans and Candida glabrata are the major causes of vulvovaginal candidiasis (VVC) in Indian women with diabetes mellitus. Little information is available regarding the genotyping of Candida species isolated from Indian diabetic women with VVC. METHODS: In this study, a total of 57 Candida species, comprising Candida albicans and Candida glabrata, isolated from Indian women with VVC, were genotyped and tested for fluconazole susceptibility. Arbitrarily primed polymerase chain reaction (AP-PCR) was used to genotype C glabrata isolates, whereas Southern blot hybridization using a Candida albicans repetitive element-2 (CARE-2) probe was used to genotype C albicans. RESULTS: Genotyping showed that all the C albicans isolates were genetically heterogenous. The pattern of DNA bands obtained after AP-PCR for C glabrata strains were predominantly conformed to genotype A. In vitro fluconazole-susceptibility testing of the isolates using the Clinical and Laboratory Standards Institute M27A2 protocol showed that more than 93% of the Candida isolates were susceptible. CONCLUSIONS: Ninety-five percent of the C albicans isolates analyzed were different and genetically unrelated. The analysis of the AP-PCR DNA banding pattern of C glabrata isolates showed that it resembled genotype "A". The Candida isolates were found to be susceptible to fluconazole, with minimum inhibitory concentrations ranging from 0.5 µg/mL to 8 µg/mL. This correlates with the use of fluconazole as a first-choice antifungal for treating VVC in India.


Asunto(s)
Antifúngicos/uso terapéutico , Candida albicans/genética , Candida glabrata/genética , Candidiasis Vulvovaginal/tratamiento farmacológico , Complicaciones de la Diabetes/microbiología , Fluconazol/uso terapéutico , Antifúngicos/farmacología , Candida albicans/efectos de los fármacos , Candida albicans/aislamiento & purificación , Candida glabrata/efectos de los fármacos , Candida glabrata/aislamiento & purificación , Candidiasis Vulvovaginal/complicaciones , Candidiasis Vulvovaginal/microbiología , Femenino , Fluconazol/farmacología , Genotipo , Humanos , India , Pruebas de Sensibilidad Microbiana , Tipificación Molecular , Reacción en Cadena de la Polimerasa
16.
Orv Hetil ; 152(7): 252-8, 2011 Feb 13.
Artículo en Húngaro | MEDLINE | ID: mdl-21296734

RESUMEN

UNLABELLED: Erysipelas is an acute bacterial infection of the skin predominantly caused by Streptococcus pyogenes. According to the international classification complicated erysipelas belongs to the complicated skin and soft tissue infections. Complicated infections are defined as severe skin involvement or when the infection occurs in compromised hosts. These infections frequently involve Gram-negative bacilli and anaerobic bacteria. AIMS: The aim of this study was to compare the efficacy of the empirical antibiotic therapy for the patients who were admitted to the Department of Dermatology and Allergology, University of Szeged. METHODS: The empirical therapy was started according to a previously determined protocol. The data of 158 patients with complicated skin and soft tissue infections were analyzed and the microbiology culture specimens and the isolates were also examined. RESULTS AND CONCLUSIONS: The results show that penicillin is the first choice for the treatment of erysipelas. However, the complicated skin and soft tissue infections require broad-spectrum antibiotics.


Asunto(s)
Antibacterianos/uso terapéutico , Penicilinas/uso terapéutico , Enfermedades Cutáneas Bacterianas/tratamiento farmacológico , Enfermedades Cutáneas Bacterianas/microbiología , Infecciones de los Tejidos Blandos/tratamiento farmacológico , Infecciones de los Tejidos Blandos/microbiología , Adulto , Anciano , Anciano de 80 o más Años , Complicaciones de la Diabetes/tratamiento farmacológico , Complicaciones de la Diabetes/microbiología , Erisipela/tratamiento farmacológico , Erisipela/microbiología , Cara/microbiología , Femenino , Bacterias Gramnegativas/aislamiento & purificación , Bacterias Grampositivas/aislamiento & purificación , Hospitalización , Humanos , Hungría , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Osteomielitis/diagnóstico , Osteomielitis/microbiología , Resultado del Tratamiento
17.
Res Microbiol ; 161(10): 854-60, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20868746

RESUMEN

The protective effect of bacteriophage was assessed against experimental Staphylococcus aureus lethal bacteremia in streptozotocin (STZ) induced-diabetic and non-diabetic mice. Intraperitoneal administrations of S. aureus (RCS21) of 2 × 108 CFU caused lethal bacteremia in both diabetic and non-diabetic mice. A single administration of a newly isolated lytic phage strain (GRCS) significantly protected diabetic and non-diabetic mice from lethal bacteremia (survival rate 90% and 100% for diabetic and non-diabetic bacteremic groups versus 0% for saline-treated groups). Comparison of phage therapy to oxacillin treatment showed a significant decrease in RCS21 of 5 and 3 log units in diabetic and non-diabetic bacteremic mice, respectively. The same protection efficiency of phage GRCS was attained even when the treatment was delayed up to 4 h in both diabetic and non-diabetic bacteremic mice. Inoculation of mice with a high dose (10¹° PFU) of phage GRCS alone produced no adverse effects attributable to the phage per se. These results suggest that phages could constitute valuable prophylaxis against S. aureus infections, especially in immunocompromised patients.


Asunto(s)
Bacteriemia/terapia , Terapia Biológica/métodos , Infecciones Estafilocócicas/terapia , Fagos de Staphylococcus/crecimiento & desarrollo , Animales , Antibacterianos/administración & dosificación , Carga Bacteriana , Complicaciones de la Diabetes/microbiología , Complicaciones de la Diabetes/terapia , Diabetes Mellitus/inducido químicamente , Femenino , Humanos , Ratones , Ratones Endogámicos BALB C , Oxacilina/administración & dosificación , Estreptozocina/toxicidad , Análisis de Supervivencia , Factores de Tiempo , Resultado del Tratamiento
18.
Infez Med ; 17(3): 184-7, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19838092

RESUMEN

Ecthyma gangrenosum is a well recognized cutaneous manifestation of severe, invasive infection by Pseudomonas aeruginosa usually in immunocompromised and critically ill patients. This type of infection is usually fatal. Aeromonas infection is infrequently reported as the cause of ecthyma gangrenosum. Here we show the first case described in Italy of Aeromonas hydrophila ecthyma gangrenosum in the lower extremities in an immunocompetent diabetic without bacteraemia. A 63-year-old obese diabetic male was admitted with an ulcer on his left leg, oedema, pain and fever. Throughout his hospitalization blood cultures remained sterile, but a culture of A. hydrophila was isolated following punctures from typical leg pseudomonal-ecthyma gangrenosum lesions developed after admission. The patient, questioned again, stated that a few days before he had worked in a well near his house without taking precautions. We conclude that early diagnosis and suitable antibiotic therapy are important for the management of ecthyma gangrenosum. The typical presentation of soft tissue infection of A. hydrophila should mimic a Gram-positive infection, which may result in a delay in administration of appropriate antibiotics. Moreover, A. hydrophila should be considered a possible agent for non-pseudomonal ecthyma gangrenosum in a diabetic man with negative blood cultures, in presence of anamnestical risk factors.


Asunto(s)
Aeromonas hydrophila/aislamiento & purificación , Complicaciones de la Diabetes/microbiología , Infecciones por Bacterias Gramnegativas/microbiología , Piodermia Gangrenosa/microbiología , Aeromonas hydrophila/patogenicidad , Antibacterianos/uso terapéutico , Terapia Combinada , Complicaciones de la Diabetes/tratamiento farmacológico , Complicaciones de la Diabetes/etiología , Complicaciones de la Diabetes/cirugía , Complicaciones de la Diabetes/terapia , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Infecciones por Bacterias Gramnegativas/etiología , Infecciones por Bacterias Gramnegativas/cirugía , Infecciones por Bacterias Gramnegativas/terapia , Humanos , Oxigenoterapia Hiperbárica , Italia , Traumatismos de la Pierna/microbiología , Masculino , Persona de Mediana Edad , Piodermia Gangrenosa/tratamiento farmacológico , Piodermia Gangrenosa/etiología , Piodermia Gangrenosa/cirugía , Piodermia Gangrenosa/terapia , Trasplante de Piel , Microbiología del Agua , Contaminación del Agua , Infección de Heridas/microbiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA